Contraception News and Research

Latest Contraception News and Research

Maternal Health Task Force and Ashoka to create international fellowship program for young professionals

The Maternal Health Task Force at EngenderHealth and Ashoka will partner to create the first international fellowship program that links committed young professionals with seasoned social entrepreneurs to improve maternal health in developing countries.

28 Sep 2009

The Adiana permanent contraception system supported by UK's NICE

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the United Kingdom's National Institute for Health and Clinical Excellence (NICE), in its updated guidance for hysteroscopic sterilization, supports the use of Hologic's Adiana((R)) permanent contraception system.

25 Sep 2009

NICE updates its guidance on hysteroscopic sterilization

Conceptus, Inc., developer of the Essure procedure, the first proven non-incisional permanent birth control method available, today announced that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has updated its guidance on hysteroscopic sterilization to support the use of the Essure permanent birth control procedure.

24 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

BioSante and Cell Genesys encourage stockholders to vote shares

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

18 Sep 2009

Drugs industry names the contraceptive pill as the greatest pharmacy innovation of the past 150 years

The Contraceptive Pill has been crowned the greatest pharmacy innovation of the past 150 years, by leading figures in the drugs industry.

18 Sep 2009

Higher teen births correlated to conservative religious beliefs

Rates of births to teenage mothers are strongly predicted by conservative religious beliefs, even after controlling for differences in income and rates of abortion. Researchers writing in BioMed Central's open access journal Reproductive Health have found a strong association between teenage birth rates and state-level measures of religiosity in the U.S.

17 Sep 2009

Teva announces availability of its Plan B One-Step emergency contraceptive over-the-counter

Teva Women’s Health, Inc. announced today that its Plan B® One-Step (levonorgestrel) tablet, 1.5 mg emergency contraceptive is now available at licensed U.S. retail pharmacies. Approved by the U.S. Food and Drug Administration (FDA) on July 10, Plan B® One-Step can help prevent an unintended pregnancy after unprotected sex or contraceptive failure with just one pill in one dose.

16 Sep 2009

Defective gene is linked to male infertility

Virginia Commonwealth University School of Medicine researchers have discovered a gene involved with the production of sperm that may contribute to male infertility and lead to new approaches to male contraception.

16 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Catholics for Choice supports coverage of reproductive healthcare services in healthcare policy

"Catholics believe that healthcare is a right, not a privilege. However, our vision for healthcare reform is different than the US bishops and their conservative allies, who seek to marginalize issues of reproductive health-as if people's reproductive health can be separated from their overall health. People in the United States need coverage of reproductive healthcare services, and efforts to deny this coverage based on the opinions of a small but vocal minority are unjust.

5 Sep 2009

World should contribute $23B to increase women's access to contraception, UNFPA says

The United Nations Population Fund (UNFPA) on Tuesday "appealed for the world to contribute more to improve women's health and access to contraception," Agence France-Presse reports.

4 Sep 2009

Media examine debate over UNESCO international sex education guidelines

The New York Times examines how "[a] set of proposed international sex education guidelines aimed at reducing H.I.V. infections among young people" and unplanned pregnancies, based on "more than 80 studies of sex education," has received some criticism. The release of the final guidelines, originally scheduled for next week by the United Nations Educational, Scientific and Cultural Organization (UNESCO), has been delayed.

4 Sep 2009

Catholics believe that healthcare is a right, not a privilege: Catholics for Choice

As Congress returns from the summer recess, we hope that we will soon see an honest and productive debate on truly comprehensive healthcare reform that leads to positive changes in healthcare accessibility for women and men in the United States.

4 Sep 2009

Biosante and Cell Genesys to merge after stockholders' approval

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies. On June 29, 2009, BioSante and Cell Genesys entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company.

3 Sep 2009

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. (NASDAQ:CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.

3 Sep 2009

Biosante's CEO to present an overview of the company and its impending merger with Cell Genesys

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will present an overview of the company and its impending merger with Cell Genesys (NASDAQ: CEGE) at two healthcare investment and partnering conferences during the month of September.

3 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

Emergency contraceptive tablet to help prevent an unintended pregnancy

There is good news for college students as they head back to campus this fall. A new emergency contraceptive, Plan B® One-Step (levonorgestrel) tablet, 1.5 mg, is now available at the local pharmacy for all students 17 and older.

24 Aug 2009

Contraception News and Research

Latest Contraception News and Research

Maternal Health Task Force and Ashoka to create international fellowship program for young professionals

The Adiana permanent contraception system supported by UK's NICE

NICE updates its guidance on hysteroscopic sterilization

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

BioSante and Cell Genesys encourage stockholders to vote shares

Drugs industry names the contraceptive pill as the greatest pharmacy innovation of the past 150 years

Higher teen births correlated to conservative religious beliefs

Teva announces availability of its Plan B One-Step emergency contraceptive over-the-counter

Defective gene is linked to male infertility

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Merck update on the status of telcagepant clinical development programs

Catholics for Choice supports coverage of reproductive healthcare services in healthcare policy

World should contribute $23B to increase women's access to contraception, UNFPA says

Media examine debate over UNESCO international sex education guidelines

Catholics believe that healthcare is a right, not a privilege: Catholics for Choice

Biosante and Cell Genesys to merge after stockholders' approval

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

Biosante's CEO to present an overview of the company and its impending merger with Cell Genesys

MammoSite ML radiation therapy system approved for breast cancer treatment

Emergency contraceptive tablet to help prevent an unintended pregnancy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Contraception News and Research

Latest Contraception News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in